We reasoned that like other dominantly heritable cancers, CDKN2A mutations carried in phenotypically normal SFs from FM patients could provide clues to the early molecular events that predispose FM melanocytes to malignant conversion (for review see [17]). Here, CDKN2A is linked to cancer.